With this clever design, researchers can achieve effective tumour eradication without causing severe safety issues in tumour‐bearing mice, as indicated by substantial attenuation of B cell aplasia and reduced production of interleukin 6, a proinflammatory cytokine regarded as the culprit for CRS. Here, IL6 is linked to neoplasm.